Freedom from MACCE according to eGFR groups at 12-month follow-up.

<p>Freedom from MACCE according to eGFR groups at 12-month follow-up.</p

Cardiac and antithrombotic medication at discharge.

<p>P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90mL/min group. Data are reported as number and percentage or mean ± SD; eGFR estimated glomerular filtration rate; VKA, vitamin K antagonist; INR, international normalized ratio; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers</p><p>Cardiac and antithrombotic medication at discharge.</p

Procedural characteristics.

<p>P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90mL/min group. Data are reported as number and percentage or mean ± SD; eGFR = estimated glomerular filtration rate; PCI = percutaneous coronary intervention; ACS = acute coronary syndrome; STEMI = ST-elevation myocardial infarction; NSTEMI = non ST-elevation myocardial infarction</p><p>Procedural characteristics.</p

Freedom from all-cause mortality according to eGFR groups at 12-month follow-up.

<p>Freedom from all-cause mortality according to eGFR groups at 12-month follow-up.</p

Baseline characteristics of the study population.

<p>P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90 ml/min/1.73 m² group. Data are reported as number and percentage or mean ± SD.; eGFR = estimated glomerular filtration rate; CHA₂ DS₂ VASC = C ongestive heart failure, H ypertension, A ge ≥75 years, D iabetes, prior S troke/transient ischaemic attack/systemic embolism, associated V ascular disease, A ge 65–74 years, and female S ex category; HAS-BLED = Hypertension, Abnormal liver or kidney function, prior Stroke, Bleeding history or predisposition, Labile INR, Elderly, and concomitant Drugs; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; TIA = transient ischemic attack.</p><p>Baseline characteristics of the study population.</p

Outcome events at 12-month follow-up.

<p>Data are reported as number of patients (percentage); P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90mL/min group. eGFR estimated glomerular filtration rate; MACCE, major adverse cardiac/cerebrovascular events; BARC, Bleeding Academic Research Consortium; BARC 1, minimal bleeding complication, BARC 2, requiring nonsurgical, medical intervention by a healthcare professional, leading to hospitalization or increased level of care, or prompting evaluation, but not fit to criteria of BARC>2, Major bleeding complication including fatal bleeding Data are reported as number and percentage or mean ± SD; TIA, transient ischemic attack, AKI = Acute kidney injure with >26.5 μmol/l increase of creatinine.</p><p>Outcome events at 12-month follow-up.</p

Freedom from any bleeding event according to eGFR groups at 12-month follow-up.

<p>Freedom from any bleeding event according to eGFR groups at 12-month follow-up.</p

Univariate Cox regression and multivariate nested adjusted models on the relative risk (hazard ratio) of renal impairment on all-cause mortality; major adverse cardiac and cerebrovascular events; and clinically significant bleeding (BARC 2, 3, 5) in patients with AF undergoing PCI as compared with normal eGFR (>90ml/kg/min).

<p>Model A (age (as a continuous variable), sex)</p><p>Model B (age, sex, acute coronary syndrome)</p><p>Model C (age, sex, acute coronary syndrome, previous myocardial infarction, congestive heart failure, center)</p><p>Univariate Cox regression and multivariate nested adjusted models on the relative risk (hazard ratio) of renal impairment on all-cause mortality; major adverse cardiac and cerebrovascular events; and clinically significant bleeding (BARC 2, 3, 5) in patients with AF undergoing PCI as compared with normal eGFR (>90ml/kg/min).</p